BI 54903 MD

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Asthma

Phase 2

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

WithdrawnNCT01458912

Boehringer IngelheimAsthma

Start: 2011-11-30Updated: 2011-11-23

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

WithdrawnNCT01458886

Boehringer IngelheimAsthma

Start: 2011-11-30Updated: 2013-10-31